NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger(Johns Hopkins University), Miranda Hughes(National Comprehensive Cancer Network), Steven Swanson(Dana-Farber Brigham Cancer Center), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Billy W. Loo(Cancer Institute (WIA)), Wallace Akerley(University of Utah), Jessica R. Bauman, Stephen C. Yang(Johns Hopkins University), Rudy P. Lackner(Susan Thompson Buffett Foundation), Douglas E. Wood(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Dara L. Aisner(University of Colorado System), Matthew A. Gubens(University of California, San Francisco), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Steven E. Schild(WinnMed), Michael Lanuti(Massachusetts General Hospital), M.C. Dobelbower(University of Colorado Cancer Center), Ramaswamy Govindan(University of Washington), Renato Martins(Seattle Cancer Care Alliance), Sandip Pravin Patel(University of San Diego), Rogério Lilenbaum(Yale Cancer Center), Theresa A. Shapiro(Sidney Kimmel Comprehensive Cancer Center), Lucian R. Chirieac(Brigham and Women's Hospital), Thomas J. Dilling(Moffitt Cancer Center), Leora Horn(Heidelberg University), Mark Hennon(Takeda (United States)), Thomas A. D’Amico(Cancer Institute (WIA)), Kristina M. Gregory(National Comprehensive Cancer Network), Kurt W. Tauer(St. Jude Children's Research Hospital), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), James Stevenson(Cleveland Clinic), Jules Lin(University of Michigan)
Cited by 471
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k